We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Stephen Kelly/PA Wire.

Can an aspirin a day lower your cancer risk?

It might, but not as much as a previous study suggested.

A NEW MEDICAL study carried out in the US has revealed that daily aspirin usage is associated with slightly lower cancer mortality.

Researchers working with the National Cancer Society in the US said that they examined the association between daily aspirin use and overall cancer mortality in over 100,000 test cases with no history of cancer.

This new evidence suggests that research published in March 2012 which suggested that taking an aspirin a day significantly reduced the risk of developing cancer may not have been accurate. That research had found that daily aspirin use for five years could reduce the risk of cancer by 37 per cent.

These new findings demonstrated a 16 per cent lower risk of cancer in those who had taken aspirin every day for five years.

Between 1997 and 2008, 5138 of participants died from cancer. The study ultimately found that usage of aspirin on a daily basis correlated with slightly lower cancer mortality.

Researchers did say that while the findings are encouraging, it is too early to recommend that people start taking aspirin specifically to prevent cancer. Anybody considering starting a course of aspirin should consult a pharmacist or GP first.

March 2012: Aspirin a day can help prevent and even treat cancer, study suggests>

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.